VOLUNTARY ANNOUNCEMENT Announcement on the Progress of Share Repurchase
Filed with HKEX · Stock code 2595 · · 2 pages · English
Summary by 6ix AI
GenFleet Therapeutics (Shanghai) Inc. has issued a voluntary announcement regarding its share repurchase progress. As of a specified date, the company has repurchased a total of a certain number of its H Shares, representing a small percentage of the total issued shares. The company plans to continue its share repurchase program based on market conditions, but there are no guarantees regarding timing or quantity. Shareholders and potential investors are advised to exercise caution when trading the H Shares due to the uncertainties involved.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Genfleet Therapeutics (Shanghai), Inc. on 6ix
Earlier from Genfleet Therapeutics (Shanghai)
- 2026 Interim Report
- VOLUNTARY ANNOUNCEMENT Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy in Pretreated NSCLC Presented in Oral Session at 2026 World Conference on Lung Cancer (WCLC)
- Voluntary announcement proposed share repurchase on the market
Later from Genfleet Therapeutics (Shanghai)
- Announcement pursuant to rule 13.10 of the listing rules
- VOLUNTARY ANNOUNCEMENT Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276
- Resignation of non-executive director
- List of directors and their roles and functions
- Next Day Disclosure Return
Follow Genfleet Therapeutics (Shanghai) into a list and get an email when it puts out news.
Follow Genfleet Therapeutics (Shanghai)